Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting

Annals of Allergy, Asthma and Immunology

Volumn 100, Issue 2, 2008, Pages 146-152

  Lee Wong, Mary ^a   Chou, Vivian ^a   Ogawa, Yoshiko ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL FUMARATE; SALBUTAMOL;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; EMERGENCY CARE; FEMALE; HUMAN; MALE; PARALLEL DESIGN; PEAK EXPIRATORY FLOW; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STUDENT T TEST; SYMPTOM;

EID: 39049144466     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60423-1     Document Type: Article

References (25)

1. The British guidelines on asthma management. Thorax. 1997;52(suppl 1):S1-S21.
2. National Heart, Lung, and Blood Institute. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute; 1997.
3. Arvidsson P, Larrson S, Lofdahl CG, Melander B, Svedmyr N, Wahlander L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J. 1991;4:1168-1173.
4. Van der Molen T, Postma DS, Turner MO, et al. Effects of the long acting β-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax. 1997;52:535-539.
5. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994;344:219-224.
6. Woolcock A, Lundback B, Ringdal OL, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153:1481-1488.
7. Van Noord JA, Smeets JJ, Raaijmakers JAM, et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J. 1996;9:1684-1688.
8. Bensch G, Lapidus RJ, Levine BE, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol. 2001;86:19-27.
9. Ringdal N, Derom E, Wahlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med. 1998;92:1017-1021.
10. Formoterol fumarate. Am J Health Syst Pharm. 2002;59:336-337.
11. Besbes-Ouanes L, Nouira S, Elatrous S, Knani J, Boussarsar M, Abroug F. Continuous versus intermittent nebulization of salbutamol in acute severe asthma: a randomized, controlled trial. Ann Emerg Med. 2000; 36:198-203.
12. Sympathomimetic Agents: Albuterol. Bethesda, MD: American Society of Health-System Pharmacists; 2001.
13. Blumenthal MN, Casale TB, Fink JN, Uryniak T, Casty FE. Evaluation of a non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: a controlled trial. J Allergy Clin Immunol. 1998;101:7-13.
14. Foradil aerolizer [package insert]. http://www.fda.gov/cder/foi/label/ 2006/020831s0091bl.pdf.
15. Avila-Castanon L, Casas-Becerra B, Del Rio-navarro BE, et al. Formoterol vs. albuterol administered via Turbuhaler system in the emergency treatment of acute asthma in children. Allergol Immunopathol (Madr). 2004;32:18-20.
16. Tattersfield A, Lofdahl CG, Postma DS, et al. As needed medication in asthma: randomized trial comparing formoterol, a long acting beta-agonist, with terbutaline. Lancet. 2001;357:257-261.
17. Rott Z, Bocskei C, Poczi M, et al. Formoterol (Oxis) Turbuhaler has a more favorable therapeutic index ratio than salbutamol pMDI in asthma [abstract]. Am Respir Crit Care Med. 2001;163:A590.
18. Rosenborg J, Larsson P, Rott Z, Böcskei C, Poczi M, Juhász G. Assessment of a relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Eur J Clin Pharmacol. 2002;58:S61-S67.
19. Totterman KJ, Huhti L, Sutinen E, et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur Respir J. 1998;12:573-579.
20. Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lotvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Eur J Clin Pharmacol. 2000;56:363-370.
21. Malolepszy J, Boszormenyi NG, Selroos O, Larsson P, Brander R. Safety of formoterol turbuhaler at cumulative dose of 90 μg in patients with acute bronchial obstruction. Eur Respir J. 2001;18:928-934.
22. Mann M, Chowdhury B, Sullican E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest. 2003;124:70-74.
23. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337: 1405-1411.
24. Centers for Disease Control and Prevention. Asthma prevalence and control characteristics by race/ethnicity - United States, 2002. MMWR Morb Mortal Wkly Rep. 2004;53:145-148.
25. A genome-wide search for asthma susceptibility loci in ethnically diverse populations: Collaborative Study on the Genetics of Asthma (CSGA). Nat Genet. 1997;15:389-392.